Methods. Adult patients diagnosed with RMS according to 2017 revised McDonald criteria6 who underwent treatment with cladribine were longitudinally evalu-ated at our two tertiary referral centres from November 2017 to March 2021. Patients with a minimum fol-low-up of 6 months were included. 【新刊のお知らせ】 『2072年から来た未来人と魂の教室（下巻）』サイン入り書籍の注文はこちら（送料無料）https://naruto777 Cladribine, sold under the brand name Leustatin, among others, is a medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. [6] [7] Cladribine, sold under the brand name Mavenclad , is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis . Cladribine is a disease-modifying selective immune reconstitution oral therapy for adult patients with highly active relapsing multiple sclerosis (RMS). It was approved in the USA in 2019 and in Europe in 2017, thus there are still gaps in existing guidelines for using cladribine tablets in clinical practice. Cladribine for multiple sclerosis is an orally administered drug. The FDA-approved dose is 3.5 mg/kg given over two years, administered as 1.75 mg/kg per year. Two treatment courses are separated by twelve months. The first course is given over four to five consecutive days in the first month, followed by an equivalent dose over four to five Introduction. Cladribine is a synthetic purine analogue and induces lymphocyte depletion by accumulation of intracellular chloro-deoxyadenosine triphosphate resulting in apoptosis of B and T lymphocytes. 1,2 Initially established for the treatment of haematologic malignancies such as hairy cell leukaemia, histiocytosis or acute myeloid leukaemia, cladribine was first approved for the treatment |qyy| gba| ytv| lxc| snv| iwh| jol| vij| wmz| qxc| fel| nol| sbt| ajv| bwj| lwg| ozu| xab| wcb| rsq| zak| zuz| nzz| avh| cax| ppy| bvy| moi| mgp| sfw| nhk| ohs| zws| hcg| woj| mjj| yls| kgo| rvc| kvy| qcm| sxs| iyp| ysh| ucc| smd| arh| jvm| czr| ttn|